Ascendis Pharma announces YORVIPATH's FDA approval and availability for treating adult hypoparathyroidism in the U.S.Quiver AI SummaryAscendis Pharma A/S has announced that its medication YORVIPATH® (palopegteriparatide),...
The Phase 2 trial of TransCon hGH in Turner syndrome showed comparable safety and growth benefits to daily somatropin.Quiver AI SummaryAscendis Pharma announced positive results from the Week 26 analysis...
Ascendis Pharma's supplemental application for SKYTROFA in adult GHD has been accepted by the FDA, aiming for broader patient access.Quiver AI SummaryAscendis Pharma A/S announced that the FDA has accepted...
Lagoa Salgada poised to become the next new mine on the Iberian Pyrite Belt
BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon?